162 related articles for article (PubMed ID: 22150538)
1. Does the oral adsorbent AST-120 really improve symptoms for non-constipating irritable bowel syndrome?
Flood R; Donnellan C
Aliment Pharmacol Ther; 2012 Jan; 35(1):197-8; author reply 198-9. PubMed ID: 22150538
[No Abstract] [Full Text] [Related]
2. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
Tack JF; Miner PB; Fischer L; Harris MS
Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
[TBL] [Abstract][Full Text] [Related]
3. Carbon-based compounds emerging as sparkling diamonds for IBS treatment?
Chao CY; Holtmann GJ
Aliment Pharmacol Ther; 2012 Jan; 35(1):199-200; author reply 200-2. PubMed ID: 22150540
[No Abstract] [Full Text] [Related]
4. End points in irritable bowel syndrome.
Mangel AW; Fehnel SE
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):293-5. PubMed ID: 21651345
[No Abstract] [Full Text] [Related]
5. How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?
Tack J
Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):21-6. PubMed ID: 23859757
[TBL] [Abstract][Full Text] [Related]
6. New and Investigational Agents for Irritable Bowel Syndrome.
Wadhwa A; Camilleri M; Grover M
Curr Gastroenterol Rep; 2015 Dec; 17(12):46. PubMed ID: 26446557
[TBL] [Abstract][Full Text] [Related]
7. Eluxadoline approved for irritable bowel syndrome with diarrhea.
Traynor K
Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
[No Abstract] [Full Text] [Related]
8. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
[TBL] [Abstract][Full Text] [Related]
9. Lubiprostone (Amitiza) for irritable bowel syndrome with constipation.
Med Lett Drugs Ther; 2008 Jul; 50(1290):53-4. PubMed ID: 18617872
[No Abstract] [Full Text] [Related]
10. Use of Treatments for Irritable Bowel Syndrome and Patient Satisfaction Based on the IBS in America Survey.
Rangan V; Ballou S; Shin A; Camilleri M; ; Lembo A
Gastroenterology; 2020 Feb; 158(3):786-788.e1. PubMed ID: 31711922
[TBL] [Abstract][Full Text] [Related]
11. The Lactulose Breath Test in Irritable Bowel Syndrome: Is It All Hot Air?
Burgell RE; Gibson PR
Dig Dis Sci; 2016 Mar; 61(3):655-7. PubMed ID: 26547755
[No Abstract] [Full Text] [Related]
12. Linaclotide for treatment of irritable bowel syndrome--the view of European regulators.
Berntgen M; Enzmann H; Schabel E; Prieto Yerro C; Gómez-Outes A; Salmonson T; Musaus J
Dig Liver Dis; 2013 Sep; 45(9):724-6. PubMed ID: 23701993
[No Abstract] [Full Text] [Related]
13. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
[No Abstract] [Full Text] [Related]
14. [A new remedy for diarrheal irritable bowel syndrome].
Storr M
MMW Fortschr Med; 2016 Mar; 158(5):43. PubMed ID: 26979218
[No Abstract] [Full Text] [Related]
15. [Treatment experience of patients with irritable bowel syndrome complicated by constipations with medicinal preparation softovak].
Ruchkina IN; Lychkova AE; Parfenov AI
Eksp Klin Gastroenterol; 2007; (5):103-6. PubMed ID: 18389606
[No Abstract] [Full Text] [Related]
16. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
Vazquez-Roque MI; Bouras EP
Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
[TBL] [Abstract][Full Text] [Related]
17. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome.
Chang L; Lembo A; Sultan S
Gastroenterology; 2014 Nov; 147(5):1149-72.e2. PubMed ID: 25224525
[No Abstract] [Full Text] [Related]
18. American Gastroenterological Association Institute Guideline on the pharmacological management of irritable bowel syndrome.
Weinberg DS; Smalley W; Heidelbaugh JJ; Sultan S;
Gastroenterology; 2014 Nov; 147(5):1146-8. PubMed ID: 25224526
[No Abstract] [Full Text] [Related]
19. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
20. Review article: tegaserod -- the global experience.
Chey WD
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():15-9. PubMed ID: 15521850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
